In contrast, SAS exhibited the lowest proportion of TMB-high cases in the overall cohort (10%) and in KRAS- (19%) and EGFR-altered (2%) non-Sq NSCLC (Fig. 4a, Supplementary Data 14). This evidence concerns the gene KRAS and non-small cell lung carcinoma.